Programmed packaging of mesoporous silica nanocarriers for matrix metalloprotease 2-triggered tumor targeting and release

Biomaterials

Volumn 58, Issue , 2015, Pages 35-45

  Zou, Zhen ^a   He, Xiaoxiao ^a   He, Dinggeng ^a   Wang, Kemin ^a   Qing, Zhihe ^a   Yang, Xue ^a   Wen, Li ^a   Xiong, Jun ^a   Li, Liling ^a   Cai, Linli ^a  

^a HUNAN UNIVERSITY   (China)

Author keywords

Gelatin; Matrix metalloproteinases 2; PEG deshielding; Programmed packaging; Tumor targeting

Indexed keywords

CARDIOVASCULAR SYSTEM; CONTROLLED DRUG DELIVERY; GELATION; LIGANDS; MESOPOROUS MATERIALS; MOLECULAR BIOLOGY; NANOPARTICLES; SILICA; SILICA NANOPARTICLES; TUMORS;

DESHIELDING; GELATIN; MATRIX METALLOPROTEASE 2; MATRIX METALLOPROTEINASES; MESOPOROUS SILICA NANOPARTICLES; MULTIFUNCTIONAL NANOCARRIER; TEMPERATURE-INDUCED GELATION; TUMOR TARGETING;

TARGETED DRUG DELIVERY;

DOXORUBICIN; FOLATE RECEPTOR; FOLIC ACID; GELATIN; GELATINASE A; LIGAND; MACROGOL; NANOCARRIER; SILICA NANOPARTICLE; SILICON DIOXIDE; ANTINEOPLASTIC AGENT; CONDITIONED MEDIUM; DRUG CARRIER; MMP2 PROTEIN, HUMAN; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCOMPATIBILITY; CANCER THERAPY; CELL VIABILITY; CIRCULATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PACKAGING; DRUG PENETRATION; DRUG RELEASE; DRUG UPTAKE; ENDOCYTOSIS; FEMALE; GELATION; HUMAN; HUMAN CELL; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MOUSE; MTT ASSAY; MULTICELLULAR SPHEROID; NONHUMAN; POROSITY; PRIORITY JOURNAL; TEMPERATURE; TUMOR CELL; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL LINE; CHEMISTRY; CONDITIONED MEDIUM; CYTOLOGY; HT 29 CELL LINE; LIVER; MALE; METABOLISM; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; DOXORUBICIN; DRUG CARRIERS; ENDOCYTOSIS; FOLIC ACID; GELATIN; HT29 CELLS; HUMANS; LIGANDS; LIVER; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; SILICON DIOXIDE;

EID: 84929241678     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.04.034     Document Type: Article

References (42)

1. Bourzac K. Carrying drugs. Nature 2012, 491:S58-S60.
2. Hubbell J., Chilkoti A. Nanomaterials for drug delivery. Science 2012, 337:303-305.
3. Huang S., Shao K., Kuang Y., Liu Y., Li J., Jiang C., et al. Tumor targeting and microenvironment-responsive nanoparticles for gene delivery. Biomaterials 2013, 34:5294-5302.
4. Matsumura Y., Maeda H. Anew concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46:6387-6392.
5. Peer D., Karp J., Hong S., Farokhzad O., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
6. Danhier F., Feron O., Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. JControl Release 2010, 148:135-146.
7. Byrne J., Betancourt T., Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 2008, 60(15):1615-1626.
8. You J., Guo P., Auguste D.T. Adrug-delivery vehicle combining the targeting and thermal ablation of HER2+ breast-cancer cells with triggered drug release. Angew Chem Int Ed 2013, 52:4141-4146.
9. Kima H., Nama K., Kima S. Tumor targeting RGD conjugated bio-reducible polymer for VEGF siRNA expressing plasmid delivery. Biomaterials 2014, 35:7543-7552.
10. Li L., Yin Q., Cheng J., Lu Y. Polyvalent mesoporous silica nanoparticle-aptamer bioconjugates target breast cancer cells. Adv Healthc Mater 2012, 1(5):567-572.
11. Zhu G., Zheng J., Song E., Donovana M., Zhang K., Tan W., et al. Self-assembled, aptamer-tethered DNA nanotrains for targeted transport of molecular drugs in cancer theranostics. Proc Natl Acad Sci U S A 2013, 110:7998-8003.
12. Zuber G., Zammut-Italiano L., Dauty E., Behr J. Targeted gene delivery to cancer cells: directed assembly of nanometric DNA particles coated with folic acid. Angew Chem Int Ed 2003, 42:2666-2669.
13. Cheng Z., Zaki A., Hui J., Muzykantov V., Tsourkas A. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 2012, 337:903-910.
14. McNeeley K., Annapragada A., Bellamkonda R. Decreased circulation time offsets increased efficacy of PEGylated nanocarriers targeting folate receptors of glioma. Nanotechnology 2007, 18:385101.
15. Chen W., Zhang A., Li S. Limitations and niches of the active targeting approach for nanoparticle drug delivery. Eur J Nanomed 2012, 4:89-93.
16. Wang Y., Wang K., Zhao J., Liu X., Bu J., Huang R., et al. Multifunctional mesoporous silica-coated graphene nanosheet used for chemo-photothermal synergistic targeted therapy of glioma. JAm Chem Soc 2013, 135(12):4799-4804.
17. Dhar S., Kolishetti N., Lippard S., Farokhzad O. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy invivo. Proc Natl Acad Sci U S A 2011, 108:1850-1855.
18. Zhang Q., Liu F., Nguyen K., Ma X., Wang X., Zhao Y., et al. Multifunctional mesoporous silica nanoparticles for cancer-targeted and controlled drug delivery. Adv Funct Mater 2012, 22:5144-5156.
19. He Q., Zhang J., Shi J., Zhu Z., Zhang L., Chen Y., et al. Biomaterials 2010, 31:1085-1092.
20. Tang F., Li L., Chen D. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv Mater 2012, 24:1504-1534.
21. Sawant R., Hurley J., Salmaso S., Kale A., Tolcheva E., Torchilin V., et al. "SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjugate Chem 2006, 17:943-949.
22. Gao W., Xiang B., Meng T., Liu F., Qi X. Chemotherapeutic drug delivery to cancer cells using a combination of folate targeting and tumor microenvironment-sensitive polypeptides. Biomaterials 2013, 34:4137-4149.
23. Romberg B., Hennink W., Storm G. Sheddable coatings for long-circulating nanoparticles. Pharm Res 2008, 25:55-71.
24. Giannelli G., Falk-Marzillier J., Schiraldi O., Stetler-Stevenson W., Quaranta V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997, 277(5323):225-228.
25. Chen W., Luo G., Lei Q., Jia H., Hong S., Zhang X., et al. MMP-2 responsive polymeric micelles for cancer-targeted intracellular drug delivery. Chem Commun 2015, 51:465-468.
26. Zhu L., Kate P., Torchilin V. Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. ACS Nano 2012, 6(4):3491-3498.
27. Zhu L., Wang T., Perche F., Taigind A., Torchilin V. Enhanced anticancer activity of nanopreparation containing an MMP2-sensitive PEG-drug conjugate and cell-penetrating moiety. Proc Natl Acad Sci U S A 2013, 110:17047-17052.
28. Wang H., Yang X., Sun C., Mao C., Zhu Y., Wang J. Matrix metalloproteinase 2-responsive micelle for siRNA delivery. Biomaterials 2014, 35:7622-7634.
29. Lu Z., Yeh T., Tsai M., Au J., Wientjes M. Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy. Clin Cancer Res 2004, 10:7677-7684.
30. Kaul G., Amiji M. Long-circulation poly(ethylene glycol)-modified gelatin nanoparticles for intracellular delivery. Pharm Res 2002, 19:1061-1067.
31. Wong C., Stylianopoulos T., Cui J., Martin J., Chauhan V., Fukumura D., et al. Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc Natl Acad Sci U S A 2011, 108:2426-2431.
32. Nakamura T., Akita H., Yamada Y., Hatakeyama H., Harashima H. Amultifunctional envelope-type nanodevice for use in nanomedicine: concept and applications. Acc Chem Res 2012, 45(7):1113-1121.
33. Zhang J., Yuan Z., Wang Y., Chen W., Luo G., Zhang X., et al. Multifunctional envelope-type mesoporous silica nanoparticles for tumor-triggered targeting drug delivery. JAm Chem Soc 2013, 135(13):5068-5073.
34. Kogure K., Akita H., Harashima H. Multifunctional envelope-type nano device for non-viral gene delivery: oncept and application of programmed Packaging. JControl Release 2007, 122:246-251.
35. Hatakeyama H., Akita H., Harashima H. Amultifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. Adv Drug Deliv Rev 2011, 63:152-160.
36. He Q., Shi J. MSN Anti-Cancer nanomedicines: chemotherapy enhancement, overcoming of drug resistance, and metastasis inhibition. Adv Mater 2014, 26:391-411.
37. Li Z., Barnes J., Bosoy A., Stoddart J., Zink J. Mesoporous silica nanoparticles in biomedical applications. Chem Soc Rev 2012, 41:2590-2605.
38. Yang P., Gai S., Lin J. Functionalized mesoporous silica materials for controlled drug delivery. Chem Soc Rev 2012, 41:3679-3698.
39. Lee C., Lin T., Mou C. Mesoporous materials for encapsulating enzymes. Nano Today 2009, 4(2):165-179.
40. Xu J., Gao F., Li L., Mab H., Zhao X., Wang H. Gelatin-mesoporous silica nanoparticles as matrix metalloproteinases-degradable drug delivery systems invivo. Microporous Mesoporous Mater 2013, 182:165-172.
41. Wan Y., Han J., Fan G., Zhang Z., Gong T., Sun X. Enzyme-responsive liposomes modified adenoviral vectors for enhanced tumor cell transduction and reduced immunogenicity. Biomaterials 2013, 34:3020-3030.
42. Desoize B., Jardillier J. Multicellular resistance: a paradigm for clinical resistance?. Crit Rev Oncol Hematol 2000, 36(2-3):193-207.